

08/10/01

09/605,599

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:19:10 ON 10 AUG 2001

=&gt; file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 12:19:58 ON 10 AUG 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 9 AUG 2001 HIGHEST RN 350981-09-8

DICTIONARY FILE UPDATES: 9 AUG 2001 HIGHEST RN 350981-09-8

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

=&gt; e arginine/cn

E1 1 ARGININANILIDE,  
N.ALPHA.,N.OMEGA.,N.OMEGA.-TRIS(PHENYLCARBAM  
OYL)-, L-/CN

E2 1 ARGININANILIDE, N2-BENZOYL-/CN

E3 2 --> ARGinine/CN

E4 1 ARGinine .BETA.-NAPHTHYLAMIDE/CN

E5 1 ARGinine 2,2,2-TRICHLOROETHYL ESTER/CN

E6 1 ARGinine 2-MONOOXYGENASE/CN

E7 1 ARGinine 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN  
(E SCHERICHTIA COLI O157:H7 STRAIN EDL933 GENE ARTI)/CN

E8 1 ARGinine 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN  
(E SCHERICHTIA COLI O157:H7 STRAIN EDL933 GENE ARTJ)/CN

E9 1 ARGinine 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN  
(E SCHERICHTIA COLI STRAIN O157:H7 GENE ECS0943)/CN

E10 1 ARGinine 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN  
(E SCHERICHTIA COLI STRAIN O157:H7 GENE ECS0946)/CN

E11 1 ARGinine 3RD TRANSPORT SYSTEM PERMEASE PROTEIN  
(ESCHERICHTIA COLI O157:H7 STRAIN EDL933 GENE ARTM)/CN

E12 1 ARGinine 3RD TRANSPORT SYSTEM PERMEASE PROTEIN  
(ESCHERICHTIA

=> s e3

L1 2 ARGININE/CN

=> file ca, uspatfull, medline, biosis, toxlit, toxline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.11	4.26

FILE 'CA' ENTERED AT 12:20:41 ON 10 AUG 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:20:41 ON 10 AUG 2001  
 CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:20:41 ON 10 AUG 2001

FILE 'BIOSIS' ENTERED AT 12:20:41 ON 10 AUG 2001  
 COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'TOXLIT' ENTERED AT 12:20:41 ON 10 AUG 2001

FILE 'TOXLINE' ENTERED AT 12:20:41 ON 10 AUG 2001

=> s l1

L2 .80894 L1

=> s controlled(3a)releas####

L3 51312 CONTROLLED(3A) RELEAS####

=> s sustained(3a)releas####

L4 48644 SUSTAINED(3A) RELEAS####

=> s l3 or l4

L5 93029 L3 OR L4

=> s extended(3a)release####

L6 6123 EXTENDED(3A) RELEASE####

=> s l6 or l5

L7 97440 L6 OR L5

=> s l7 and l2

L8 247 L7 AND L2

=> dup remove l8

PROCESSING COMPLETED FOR L8

L9 196 DUP REMOVE L8 (51 DUPLICATES REMOVED)

=> s tablet#

L10 216886 TABLET#

=> s 110 and 19

L11 61 L10 AND L9

=> s sustained(5a)matrix

L12 2061 SUSTAINED(5A) MATRIX

=> s 112 and 111

L13 0 L12 AND L11

=> s 112 and 18

L14 4 L12 AND L8

=> s 112 and 12

L15 8 L12 AND L2

=> s 114 or 115

L16 8 L14 OR L15

=> dup remove 116

PROCESSING COMPLETED FOR L16

L17 8 DUP REMOVE L16 (0 DUPLICATES REMOVED)

=> d 117 1-8 bib,ab

L17 ANSWER 1 OF 8 USPATFULL

AN 2001:111858 USPATFULL

TI Methods for increasing vascularization and promoting wound healing

IN Usala, Anton-Lewis, 237 Buckingham Dr., Winterville, NC, United States  
28590

PI US 6261587 B1 20010717

AI US 1999-337959 19990622 (9)

RLI Continuation-in-part of Ser. No. US 1998-113437, filed on 10 Jul 1998

DT Utility

FS GRANTED

EXNAM Primary Examiner: Azpuru, Carlos A.

LREP Alston & Bird LLP

CLMN Number of Claims: 57

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 713

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method of stimulating vascularization  
at a site in a mammal, said method comprising contacting said site with  
a matrix comprising gelatin and a nitric oxide inhibitor. The gelatin

is preferably denatured collagen. The nitric oxide inhibitor may be a  
sulfonated moiety. The inhibitor may be an L-arginine analog, such as  
aminoguanidine, N-monoethyl L-arginine, N-nitro-L-arginine and  
D-arginine. The matrix may further comprise a nitric oxide scavenger,  
such as dextran, heparin, cysteine and cystine.

L17 ANSWER 2 OF 8 USPATFULL

AN 2001:97890 USPATFULL

TI Antiangiogenic peptides and methods for inhibiting angiogenesis

IN Davidson, Donald J., Gurnee, IL, United States

PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

PI US 6251867 B1 20010626  
AI US 1998-132154 19980811 (9)  
RLI Continuation of Ser. No. US 1998-132154, filed on 11 Aug 1998 And Ser.  
No. US 1997-832087, filed on 3 Apr 1997 Continuation-in-part of Ser.  
No.  
US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Hendricks, Keith D.; Assistant Examiner: Stole, Einar  
LREP Steele, Gregory W., Casuto, Dianne  
CLMN Number of Claims: 4  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 2101  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Mammalian kringle 5 fragments are disclosed as a compounds for treating  
angiogenic diseases. Methods and compositions for inhibiting angiogenic  
diseases are also disclosed.

L17 ANSWER 3 OF 8 USPATFULL  
AN 2001:71117 USPATFULL  
TI Medium and matrix for long-term proliferation of cells  
IN Usala, Anton-Lewis, 237 Buckingham Dr., Winterville, NC, United States  
28590  
Klann, Richard Chris, 239 E. Main St., Washington, NC, United States  
27889

PI US 6231881 B1 20010515  
AI US 1998-113437 19980710 (9)  
RLI Continuation-in-part of Ser. No. US 1995-568482, filed on 7 Dec 1995,  
now patented, Pat. No. US 5834005 Continuation-in-part of Ser. No. US  
1994-300429, filed on 2 Sep 1994, now abandoned Continuation-in-part of  
Ser. No. US 1992-841973, filed on 24 Feb 1992, now abandoned

DT Utility  
FS Granted  
EXNAM Primary Examiner: Azpuru, Carlos A.  
LREP Alston & Bird LLP  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1020

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A cell culture medium and hydrogel matrix for long term storage and  
proliferation of cells is provided. The cell culture medium and  
hydrogel

matrix include an effective amount of polar amino acids, the polar  
amino

acids selected from the group consisting of arginine, lysine,  
histidine,

glutamic acid, and aspartic acid. The cell culture medium comprises  
about 5 to about 150 mM of polar amino acids. The hydrogel matrix  
comprises about 3 to about 150 mM of polar amino acids. Arginine and  
glutamic acid are preferably supplemented in the cell culture medium.  
Arginine, lysine, and glutamic acid are preferably supplemented in the  
hydrogel matrix. A method of maintaining viability and functioning of a  
transplant is also provided. The method of maintaining viability of a  
transplant includes encapsulating the cells in a hydrogel matrix and  
injecting the encapsulated cells into the host organism. The matrix of  
the present invention may also be used to promote vascularization in a  
transplant site prior to injection of cells.

L17 ANSWER 4 OF 8 USPATFULL  
AN 1999:132781 USPATFULL  
TI Antiangiogenic peptides and methods for inhibiting angiogenesis  
IN Davidson, Donald J., Gurnee, IL, United States  
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

PI US 5972896 19991026  
AI US 1998-131995 19980811 (9)  
RLI Continuation of Ser. No. US 1997-832087, filed on 3 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Stole, Einar  
LREP Steele, Gregory W., Casuto, Dianne  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 2444  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

L17 ANSWER 5 OF 8 USPATFULL  
AN 1998:134650 USPATFULL  
TI Bioartificial devices and cellular matrices therefor  
IN Usala, Anton-Lewis, Winterville, NC, United States  
PA Encelle, Inc., United States (U.S. corporation)  
PI US 5830492 19981103  
AI US 1995-568694 19951207 (8)  
RLI Continuation-in-part of Ser. No. US 1994-300429, filed on 2 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-841973, filed on 24 Feb 1992, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Azpuru, Carlos  
LREP Alston & Bird, LLP  
CLMN Number of Claims: 21  
ECL Exemplary Claim: 1  
DRWN 37 Drawing Figure(s); 20 Drawing Page(s)  
LN.CNT 1509  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A device for the effective release of cellular moieties, including hormones, wherein a matrix containing a hormone producing cellular moiety is encapsulated with a non-immunogenic polymeric material of poly-para-xylylene or other aromatic based moiety having a membrane portion with a porosity blocking passage therethrough of immunogenic agents and permitting passage therethrough of effective nutrients for said cellular moiety and the hormone produced thereby, an improved matrix for the storage, manufacture, functional testing, and viral infection testing of cellular moieties wherein a collagen based hydrogel is processed to present a liquid phase at host temperature and functions as a substrate for cellular attachment with additives effective for limiting thermal and pressure trauma, and an improved method for the harvesting tissue from organs.

L17 ANSWER 6 OF 8 USPATFULL  
AN 1998:127929 USPATFULL  
TI Bioartificial devices and cellular matrices therefor  
IN Usala, Anton-Lewis, Winterville, NC, United States  
PA Encelle, Inc., United States (U.S. corporation)  
PI US 5824331 19981020  
AI US 1995-568503 19951207 (8)  
RLI Continuation-in-part of Ser. No. US 1994-300429, filed on 2 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-841973, filed on 24 Feb 1992, now abandoned  
DT Utility  
FS Granted

EXNAM Primary Examiner: Azpuru, Carlos  
LREP Alston & Bird, LLP  
CLMN Number of Claims: 51  
ECL Exemplary Claim: 1  
DRWN 37 Drawing Figure(s); 20 Drawing Page(s)  
LN.CNT 1549

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A device for the effective release of cellular moieties, including hormones, wherein a matrix containing a hormone producing cellular moiety is encapsulated with a nonimmunogenic polymeric material of poly-para-xylylene or other aromatic based polymeric moiety having a membrane portion with a porosity blocking passage therethrough of immunogenic agents and permitting passage therethrough of effective nutrients for said cellular moiety and the hormone produced thereby, an improved matrix for the storage, manufacture, functional testing, and viral infection testing of cellular moieties wherein a collagen based hydrogel is processed to present a liquid phase at host temperature and functions as a substrate for cellular attachment with additives effective for limiting thermal and pressure trauma, and an improved method for the harvesting tissue from organs.

L17 ANSWER 7 OF 8 USPATFULL

AN 1998:104717 USPATFULL

TI Compound and method for inhibiting angiogenesis

IN Davidson, Donald J., Gurnee, IL, United States

PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

PI US 5801146 19980901

AI US 1996-643219 19960503 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Stole, Einar

LREP Steele, Gregory W., Casuto, Dianne

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 12 Drawing Page(s)

LN.CNT 1510

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian kringle 5 is disclosed as a compound for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

L17 ANSWER 8 OF 8 CA COPYRIGHT 2001 ACS

AN 106:38499 CA

TI Antitumor depot

IN Wahlig, Helmut; Dingeldein, Elvira

PA Merck Patent G.m.b.H., Fed. Rep. Ger.

SO Ger. Offen., 16 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3513938	A1	19861023	DE 1985-3513938	19850418
	AU 8654656	A1	19861023	AU 1986-54656	19860312
	AU 587432	B2	19890817		
	EP 202445	A2	19861126	EP 1986-104723	19860407
	EP 202445	A3	19870812		
	EP 202445	B1	19910220		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AT 60904	E	19910315	AT 1986-104723	19860407
	CA 1282330	A1	19910402	CA 1986-506775	19860416
	JP 61243015	A2	19861029	JP 1986-87256	19860417
	HU 44170	A2	19880229	HU 1986-1608	19860417
	HU 198383	B	19891030		

	ES 554090	A1	19880316	ES 1986-554090	19860417
	ZA 8602947	A	19870930	ZA 1986-2947	19860418
PRAI	DE 1985-3513938		19850418		
	EP 1986-104723		19860407		

AB An implantable **sustained-release** depot for the treatment of tumor contains a cytostatic agent and an amino acid (particle size <125 .mu.m) incorporated into polyacrylate and/or polymethacrylate. Thus, 39.2 g bead poly(Me acrylate-Me methacrylate), contg. 0.5% Bz202 at traces of chlorophyll, was mixed with 0.8 g L-arginine, 0.5 g methotrexate and 20 mL Me methacrylate, contg. 0.7% dimethyl-p-toluidine and 0.006% hydroquinone, to give an antitumor implant.

09/605,599

=> log y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION  
35.86

FULL ESTIMATED COST

31.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY

TOTAL  
SESSION  
-0.56

CA SUBSCRIBER PRICE

-0.56

STN INTERNATIONAL LOGOFF AT 12:25:31 ON 10 AUG 2001